The First People's Hospital of Changzhou
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1918-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.czfph.com/en
Clinical Trial of Safety and Efficacy of Intracranial Laser Balloon Dilation Catheter in Patients With Symptomatic Intracranial Atherosclerotic Stenosis: A Prospective, Multi-center, Randomized Comparison
Not Applicable
- Conditions
- Prospective, Multicenter, Randomized, Controlled, and Superior Efficiency
- First Posted Date
- 2025-04-30
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- The First People's Hospital of Changzhou
- Target Recruit Count
- 128
- Registration Number
- NCT06950242
- Locations
- 🇨🇳
The First People's Hospital of Changzhou., Changzhou, Jiangsu, China
Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis
Phase 3
Recruiting
- Conditions
- Anti-N-Methyl-D-Aspartate Receptor Encephalitis
- Interventions
- Drug: Ofatumumab combined with daratumumabDrug: Repeated intravenous immunoglobulin/plasma exchange therapy
- First Posted Date
- 2025-03-10
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- The First People's Hospital of Changzhou
- Target Recruit Count
- 200
- Registration Number
- NCT06867991
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳The First People's Hospital of Changzhou, Changzhou, Jiangsu, China
Wingspan Stent System for Intracranial Artery Stenosis
Completed
- Conditions
- Intracranial Artery StenosisStentEndovascular Therapy
- Interventions
- Device: Wingspan stent system
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- The First People's Hospital of Changzhou
- Target Recruit Count
- 43
- Registration Number
- NCT06618222
- Locations
- 🇨🇳
The First People's Hospital of Changzhou, Changzhou, Jiangsu, China
Regorafenib and Sintilimab in Combination with Electroacupuncture in MSS CRC
Not Applicable
Recruiting
- Conditions
- Colorectal Cancer Metastatic
- Interventions
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- The First People's Hospital of Changzhou
- Target Recruit Count
- 30
- Registration Number
- NCT06456515
- Locations
- 🇨🇳
The First People's Hospital of Changzhou, Changzhou, China
Efficacy of Henagliflozin for Weight Loss in Obesity Without Diabetes
Phase 4
Not yet recruiting
- Conditions
- ObeseWeight LossPre-diabetes
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- The First People's Hospital of Changzhou
- Target Recruit Count
- 300
- Registration Number
- NCT06216340
SBRT Combined With AK104 to Treatment Relapsed or Metastatic ESCC
Phase 2
Not yet recruiting
- Conditions
- Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
- Interventions
- Radiation: SBRT
- First Posted Date
- 2023-02-17
- Last Posted Date
- 2023-02-17
- Lead Sponsor
- The First People's Hospital of Changzhou
- Target Recruit Count
- 25
- Registration Number
- NCT05732662
SOX Versus XELOX for Patients With Peritoneal Metastasis of Colorectal Cancer
Phase 2
- Conditions
- Colorectal Neoplasm
- Interventions
- Drug: SOXDrug: XELOX
- First Posted Date
- 2016-08-17
- Last Posted Date
- 2016-08-19
- Lead Sponsor
- The First People's Hospital of Changzhou
- Target Recruit Count
- 60
- Registration Number
- NCT02870153
- Locations
- 🇨🇳
The First People's Hospital of Changzhou, Changzhou, Jiangsu, China
Microwave Ablation for Pulmonary Metastases From Colorectal Cancer
Not Applicable
Completed
- Conditions
- Colorectal Cancer
- Interventions
- Device: microwave ablation
- First Posted Date
- 2015-07-20
- Last Posted Date
- 2016-08-15
- Lead Sponsor
- The First People's Hospital of Changzhou
- Target Recruit Count
- 32
- Registration Number
- NCT02502630
Cytokine-induced Killer Study for Patients With Stage II Melanoma
Phase 2
Not yet recruiting
- Conditions
- Melanoma
- Interventions
- Biological: Cytokine-induced killer cells
- First Posted Date
- 2015-07-15
- Last Posted Date
- 2015-07-15
- Lead Sponsor
- The First People's Hospital of Changzhou
- Target Recruit Count
- 300
- Registration Number
- NCT02498756
Treatment of CIK for Patients With Refractory Non-Hodgkin Lymphoma
Phase 2
Not yet recruiting
- Conditions
- Lymphoma, Non-Hodgkin
- Interventions
- Biological: Cytokine-induced killer cells (CIK)
- First Posted Date
- 2015-07-15
- Last Posted Date
- 2015-07-15
- Lead Sponsor
- The First People's Hospital of Changzhou
- Target Recruit Count
- 1000
- Registration Number
- NCT02497898
© Copyright 2025. All Rights Reserved by MedPath